CellabMED is an R&D-oriented company.

CellabMED is a leader in innovative and efficient new drug development based on its know-how and experience from R&D through clinical trials and ultimately manufacturing.

We have begun Phase 1 clinical trials after receiving IND approval from the Ministry of Food and Drug Safety (MFDS) in December 2021 for Korea’s first CAR-T cell therapy indicated for the treatment of solid cancer. By establishing a GMP manufacturing facility that produces investigational products developed in-house, CellabMED is perfectly positioned to lead the development of CAR-T cell therapy.

In another advancement, HGF antibody therapeutics have been proven to be safe and effective by completing phase 1b/2a clinical trials.

CellabMED is devoted to the development of breakthrough drugs through the passionate work of highly qualified researchers.

CEO